TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33709856
Drug: Inhaled Glycopyrronium
Normalized name: glycopyrronium Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Glycopyrronium Bromide 12.5 µg BID
Study: 32897319
Drug: Mindfulness‐Based Stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness‐Based Stress Reduction (abbreviated to four weekly 90‐minute sessions)
Study: 32493462
Drug: Two sequences
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two sequences of two daily tDCS sessions over 5 days (one active and one sham)
Study: 32229495
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg)
Study: 33693863
Drug: CGRP-targeted monoclonal
Normalized name: CGRP
DrugBank: Calcitonin gene-related peptide (DB06379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGRP-targeted monoclonal antibodies (CGRP-targeted mAbs) as add-on therapy to onabotulinumtoxinA
Study: 32881699
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (infants who did not receive antibiotics)
Study: 32114185
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for insomnia (CBTI)
Study: 32799029
Drug: Sleep restriction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep restriction therapy (SRT)
Study: 38115004
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg daily)
Study: 32170355
Drug: Topical co-delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical co-delivery of platelet rich fibrin (PRF) and tranexamic acid (TA)
Study: 32170355
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (combined intravenous and topical TA)
Study: 32462642
Drug: Intraoperative tibia
Normalized name: Tilia extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative tibia fractures treatment
Study: 32160368
Drug: Topical dimethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dimethyl sulfoxide (DMSO) 50% solution
Study: 32160368
Drug: Tretinoin 0.5%
Normalized name: Tretinoin 0.5% Topical solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin 0.5% cream
Study: 36186784
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous injection of vitamin C (200 mg/kg/24 h) for 4 days
Study: 33887662
Drug: Real rTMS
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real rTMS with physical therapy (PT)
Study: 33887662
Drug: Real cTBS
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real cTBS with physical therapy (PT)
Study: 33887662
Drug: Sham cTBS
Normalized name: Syn023 component ctb-011
DrugBank: Zamerovimab (DB17766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham cTBS with physical therapy (PT)
Study: 34009177
Drug: Endoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic treatment
Study: 33394989
Drug: L-T mode
Normalized name: (T,G)-A-L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-T mode at output power of 60 W and 84 W
Study: 33394989
Drug: L mode
Normalized name: GenTeal Moderate Ophthalmic Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: L mode
Study: 33394989
Drug: L-T mode
Normalized name: (T,G)-A-L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-T mode
Study: 35366419
Drug: AJM300 (960
Approvals — FDA: no, EMA: no, PMDA: no
Description: AJM300 (960 mg) administered orally, three times daily for 8 weeks
Study: 34549819
Drug: Topical Antioxidants
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Antioxidants (AO) 2.0%
Study: 34666379
Drug: Pravastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20 mg twice daily) starting from 14 to 20 weeks' gestation until delivery
Study: 35292944
Drug: Pravastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20 mg twice daily)
Study: 34666379
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin (80 mg/day) and calcium (1 g/day)
Study: 37173784
Drug: Citicoline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline treatment
Study: 38273252
Drug: Intravenous ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ibuprofen
Study: 32866967
Drug: Metformin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2 g daily)
Study: 34121413
Drug: MEDI6012 (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI6012 (intravenous doses of 24, 80, 240, and 800 mg)
Study: 34121413
Drug: MEDI6012 (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI6012 (subcutaneous doses)
Study: 36438959
Drug: Bright Light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright Light Therapy (BLT)
Study: 35900607
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 µg sc daily for 48 weeks)
Study: 35900607
Drug: Alendronate (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (70 mg oral weekly for 48 weeks)
Study: 33909860
Drug: 1.23% acidulated
Normalized name: Nupro APF 1.23% Acidulated Phosphate Fluoride Gel (Bubblegum)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.23% acidulated phosphate fluoride (APF) gel
Study: 33109390
Drug: PCV13 2
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV13 2 + 1 (received pneumococcal conjugate vaccine 13 valent at 2, 4 and 12 months)
Study: 38927991
Drug: Nivolumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab monotherapy
Study: 32150484
Drug: Aster glehni
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aster glehni Extract (AGE) 480 mg/day
Study: 36049557
Drug: Oral everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral everolimus (days 1-3: 7.5 mg qd, days 4-5: 5.0 mg qd)
Study: 35790011
Drug: Transdermal buprenorphine
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transdermal buprenorphine solution (TBS) 8 mg (0.4 ml) for cats 1.2 to 3 kg and 20 mg (1 ml) for cats >3 to 7.5 kg, applied topically 1–2 h prior to surgery.
Study: 32102803
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) in addition to usual treatment for 16 weeks
Study: 32102803
Drug: Talking control
Normalized name: Take Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talking control in addition to usual treatment for 16 weeks
Study: 36075249
Drug: ABX464 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX464 50 mg
Study: 32704050
Drug: Self-administered questionnaire
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered questionnaire including the Dutch Musculoskeletal Questionnaire and Modified Nordic Musculoskeletal Questionnaire
Study: 35914662
Drug: Omalizumab 300
Normalized name: OMALIZUMAB 300MG/2ML INJ,SOLN,SYR,2ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab 300 mg subcutaneously every 4 weeks for 24 weeks
Study: 36398042
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate at 40 mg·kg‐1 of actual body weight
Study: 33073523
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg once daily for 13 weeks
Study: 34391006
Drug: 1 treatment
Normalized name: Selenium Sulfide 1% Topical application Shampoo [SELSUN BLUE 2 IN 1 TREATMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 treatment course of rTMS
Study: 37522226
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg
Study: 33547980
Drug: Single 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 400 μg dose of anti-GnRH vaccine (G1)
Study: 33547980
Drug: Two 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 400 μg doses of anti-GnRH vaccine (G2)
Study: 33547980
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) - 1 mL saline 0.9%
Study: 35599990
Drug: Online group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online group intervention consisting of 12 weekly modules based on cognitive-behavioral methods
Study: 34936268
Drug: Herb-separated moxibustion
Normalized name: serrated swimming crab, cooked preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herb-separated moxibustion on navel combined with Ningmitai capsule
Study: 34936268
Drug: Ningmitai capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ningmitai capsule
Study: 37428547
Drug: TAU (treatment-as-usual)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU (treatment-as-usual)
Study: 33169383
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine without intubation
Study: 33169383
Drug: Availability of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Availability of essential drugs
Study: 34236131
Drug: Skin-to-skin contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin-to-skin contact (SSC) for one hour daily for five weeks
Study: 37344262
Drug: V114 (15-valent
Approvals — FDA: no, EMA: no, PMDA: no
Description: V114 (15-valent pneumococcal conjugate vaccine)
Study: 33666305
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg risperidone
Study: 39319904
Drug: Double antibiotic
Normalized name: Double Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double antibiotic paste (DAP)
Study: 38854963
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy alone
Study: 34292199
Drug: Web-based lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based lower back exercise intervention, performed at least twice a day, four times a week for 8 weeks
Study: 32337738
Drug: Antipsychotics discontinued
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotics discontinued >90 days
Study: 35797219
Drug: additional anthracycline-containing
Normalized name: methacycline
DrugBank: Metacycline (DB00931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: additional anthracycline-containing chemotherapy
Study: 35014613
Drug: Maternal oral
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal oral vitamin D supplementation 1,20,000 IU/month for 12 months
Study: 35014613
Drug: Maternal oral
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal oral vitamin D supplementation 12,000 IU/month for 12 months
Study: 33975010
Drug: Dual combination
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual combination therapy, specifically carbapenem-polymyxin regimen
Study: 34446156
Drug: Colchicine 0.5
Normalized name: colchicine 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.5 mg once daily
Study: 33213529
Drug: Zilucoplan (32.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilucoplan (32.4 mg subcutaneously daily) plus IV ceftriaxone (2g daily for 14 days) and standard of care
Study: 33213529
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care plus IV ceftriaxone (2g daily for 1 week)
Study: 34511184
Drug: Vadadustat 150
Normalized name: vadadustat 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vadadustat 150 mg with sodium ferrous citrate
Study: 34511184
Drug: Vadadustat 150
Normalized name: vadadustat 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vadadustat 150 mg with ferric citrate hydrate
Study: 34511184
Drug: Vadadustat 150
Normalized name: vadadustat 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vadadustat 150 mg with sucroferric oxyhydroxide
Study: 34511184
Drug: Vadadustat 150
Normalized name: vadadustat 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vadadustat 150 mg with ferrous sulfate
Study: 33882893
Drug: Telemonitoring of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemonitoring of adherence to inhalation therapies, weekly home spirometry, video-conferencing, self-management app, professional telephone coaching.
Study: 36202557
Drug: MitraClip implantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MitraClip implantation plus guideline‐directed medical therapy (GDMT)
Study: 33386332
Drug: 2-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose regimen (0, 12)
Study: 33386332
Drug: 3-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose regimen (0, 2, 6)
Study: 33386332
Drug: 2-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose regimen (0, 6)
Study: 34201450
Drug: Standard Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Group and Enhanced Group received 20 smoking-related messages over 2 weeks; Enhanced Group received an extra 6 oral health-related messages for one week.
Study: 35226559
Drug: Edoxaban 15
Normalized name: edoxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 15 mg
Study: 33016374
Drug: Rivastigmine (capsules)
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine (capsules)
Study: 33016374
Drug: Rivastigmine (patch)
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine (patch)
Study: 35717820
Drug: ICI-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI-based therapy (monotherapy or combination)
Study: 35717820
Drug: VEGF inhibitor
Normalized name: Vegf receptor 2 kinase inhibitor i
DrugBank: VEGFR 2 Kinase inhibitor I (DB17061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF inhibitor monotherapy
Study: 35717820
Drug: mTOR inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: mTOR inhibitor monotherapy
Study: 38231570
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (treatment as usual).
Study: 34738161
Drug: Bolus group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus group (0.5 mg penehyclidine injected before anesthesia)
Study: 34738161
Drug: Infusion group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion group (0.25 mg penehyclidine injected before anesthesia and another 0.25 mg infused after surgery)
Study: 32811681
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy followed by radiation (CT‐RT)
Study: 32811681
Drug: Sequential radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential radiation followed by chemotherapy (RT‐CT)
Study: 32086373
Drug: Abstinence-contingent wage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abstinence-contingent wage supplements
Study: 32654156
Drug: Placebo, weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, weekly subcutaneous administration for 65 weeks
Study: 35142000
Drug: Complex Oral
Normalized name: vitamin B complex Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex Oral Semantic Fluency (COSEF) task
Study: 34305642
Drug: Nocturnal Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocturnal Oxygen Therapy (NOT) at 3 L/min
Study: 34395624
Drug: 1 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg/kg dose of nitroglycerin
Study: 34395624
Drug: 2 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg/kg dose of nitroglycerin
Study: 39698942
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drugs (NSAIDs)
Study: 33662334
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of anti-IL-21 and liraglutide
Study: 35238894
Drug: Pemafibrate 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemafibrate 0.2 mg twice a day
Study: 33069624
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of microUS-targeted and randomized biopsies
Study: 33109926
Drug: Placebo groups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo groups (informed that the application of an inert cream would reduce pain)
Study: 33109926
Drug: Nocebo groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocebo groups (informed that the application of an inert cream would amplify pain)
Study: 36446950
Drug: Aspirin (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (loading and maintenance doses)
Study: 35176208
Drug: Drugs with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs with anticholinergic properties (DAPs) prescribed to patients
Study: 35664760
Drug: supplemental home
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: supplemental home parenteral nutrition (sHPN)
Study: 34836211
Drug: TRX suspension
Normalized name: TRX-518
DrugBank: TRX-518 (DB17534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRX suspension training + placebo (TP)
Study: 34836211
Drug: TRX suspension
Normalized name: TRX-518
DrugBank: TRX-518 (DB17534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRX suspension training + taurine supplementation (TT)
Study: 34937416
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (CON)
Study: 616389141
Drug: 1 x
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 3 soft capsules of BCSO (0.5 ml each)
Study: 616389141
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 3 soft capsules of BCSO (0.5 ml each)
Study: 616389141
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 3 soft capsules of BCSO (0.5 ml each)
Study: 38627631
Drug: Cilostazol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (200 mg)
Study: 36062966
Drug: Daily GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily GH (Norditropin; 0.034 mg/kg/d)
Study: 37406251
Drug: Somapacitan (0.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somapacitan (0.16 mg/kg/wk)
Study: 33403759
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) infusion during OLDH
Study: 32589506
Drug: Volanesorsen 300
Normalized name: Volanesorsen
DrugBank: Volanesorsen (DB15067)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Volanesorsen 300 mg SC
Study: 32589506
Drug: Volanesorsen 300
Normalized name: Volanesorsen
DrugBank: Volanesorsen (DB15067)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Volanesorsen 300 mg IV
Study: 35195075
Drug: Endoscopic balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic balloon dilatation combined with submucosal injection of 40 mg prednisolone
Study: 32380660
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (1 g ferric carboxymaltose, n = 86)
Study: 32380660
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplementation (10 g iron fumarate, 100 capsules, n = 90)
Study: 36177443
Drug: Glibenclamide (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (1.25 mg, 3 times/day) with standard care
Study: 34157996
Drug: Platinum-containing dual-drug
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-containing dual-drug chemotherapy
Study: 32091594
Drug: Single-dose bivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose bivalent HPV vaccine
Study: 32091594
Drug: Two-dose bivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose bivalent HPV vaccine
Study: 32091594
Drug: Three-dose bivalent
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose bivalent HPV vaccine
Study: 35872530
Drug: Olaparib 200
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 200 mg three times a day (TDS)
Study: 32283944
Drug: Step 2
Normalized name: STEP 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step 2 maintenance treatment
Study: 36110981
Drug: Sports dance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sports dance exercises for 20-30 minutes, once a day initially, then twice a day for 180 days of continuous rehabilitation and exercise therapy.
Study: 37337261
Drug: Treatment As
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment As Usual (TAU) alone
Study: 35260342
Drug: Cetuximab (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (loading dose 400 mg/m2 day 1; subsequent weekly 250 mg/m2 doses until two weeks postradiotherapy) + Cisplatin (75 mg/m2) + Pemetrexed (500 mg/m2) + Radiotherapy (maximally 66 Gy starting on day 22)
Study: 32338756
Drug: Red meat
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red meat consumption more than twice a week for dinner
Study: 33259976
Drug: Lidocaine throat
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine throat spray
Study: 33259976
Drug: Lidocaine throat
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine throat spray and nebulized lidocaine
Study: 36038633
Drug: Spa therapy
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa therapy
Study: 33707305
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor agonists (GLP-1RAs)
Study: 35775451
Drug: Sodium‐glucose cotransporter‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium‐glucose cotransporter‐2 inhibitors (SGLT2is)
Study: 33818933
Drug: Alpha-blockers and
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-blockers and fluoroquinolones (control group)
Study: 38847412
Drug: Rocuronium 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.9 mg/kg